Comparison of the Effects of Carperitide and Tolvaptan on Patients with Left Ventricular Dysfunction: A Two-Center Retrospective Study. (scientific article published on 12 July 2017)

Vasopressin V2 receptor antagonist tolvaptan is effective in heart failure patients with reduced left ventricular systolic function and low blood pressure.

Q53589181

Increased plasma arginine vasopressin levels in patients with congestive heart failure

Q70257480

Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy

Q81441501

Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated

Q82194379

Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure

Q87447550

Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure

Q88130879

Effect of nesiritide in patients with acute decompensated heart failure

Q28242547

Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data

Q33613135

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

Q34003169

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure

Q34101478

Hypomagnesemia and concurrent acid-base and electrolyte abnormalities in patients with congestive heart failure

Q43962875

Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients

Q44604091

Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study

Q46350592

Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-

Q46468937

Tolvaptan Reduces Long-Term Total Medical Expenses and Length of Stay in Aquaporin-Defined Responders

Q49047057

P275

Creative Commons Attribution 4.0 International

copyrighted

main subject

left ventricular dysfunction